JP2020533412A - ２−（５−（４−（２−モルホリノエトキシ）フェニル）ピリジン−２−イル）−ｎ−ベンジルアセトアミドの固体形態 - Google Patents

２−（５−（４−（２−モルホリノエトキシ）フェニル）ピリジン−２−イル）−ｎ−ベンジルアセトアミドの固体形態 Download PDF

Info

Publication number
JP2020533412A
JP2020533412A JP2020536496A JP2020536496A JP2020533412A JP 2020533412 A JP2020533412 A JP 2020533412A JP 2020536496 A JP2020536496 A JP 2020536496A JP 2020536496 A JP2020536496 A JP 2020536496A JP 2020533412 A JP2020533412 A JP 2020533412A
Authority
JP
Japan
Prior art keywords
compound
solvent
polymorph according
weeks
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020536496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533412A5 (enExample
Inventor
マイケル ピー． スモリンスキ
マイケル ピー． スモリンスキ
Original Assignee
アセネックス エイチケイ イノベイティブ リミテッド
アセネックス エイチケイ イノベイティブ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65517772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020533412(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アセネックス エイチケイ イノベイティブ リミテッド, アセネックス エイチケイ イノベイティブ リミテッド filed Critical アセネックス エイチケイ イノベイティブ リミテッド
Publication of JP2020533412A publication Critical patent/JP2020533412A/ja
Publication of JP2020533412A5 publication Critical patent/JP2020533412A5/ja
Priority to JP2023107781A priority Critical patent/JP2023157909A/ja
Priority to JP2025091579A priority patent/JP2025131661A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020536496A 2017-09-07 2018-09-07 ２−（５−（４−（２−モルホリノエトキシ）フェニル）ピリジン−２−イル）−ｎ−ベンジルアセトアミドの固体形態 Pending JP2020533412A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023107781A JP2023157909A (ja) 2017-09-07 2023-06-30 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
JP2025091579A JP2025131661A (ja) 2017-09-07 2025-06-02 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07
US62/555,390 2017-09-07
PCT/US2018/049829 WO2019051147A1 (en) 2017-09-07 2018-09-07 SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023107781A Division JP2023157909A (ja) 2017-09-07 2023-06-30 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態

Publications (2)

Publication Number Publication Date
JP2020533412A true JP2020533412A (ja) 2020-11-19
JP2020533412A5 JP2020533412A5 (enExample) 2021-09-30

Family

ID=65517772

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020536496A Pending JP2020533412A (ja) 2017-09-07 2018-09-07 ２−（５−（４−（２−モルホリノエトキシ）フェニル）ピリジン−２−イル）−ｎ−ベンジルアセトアミドの固体形態
JP2023107781A Pending JP2023157909A (ja) 2017-09-07 2023-06-30 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
JP2025091579A Pending JP2025131661A (ja) 2017-09-07 2025-06-02 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023107781A Pending JP2023157909A (ja) 2017-09-07 2023-06-30 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
JP2025091579A Pending JP2025131661A (ja) 2017-09-07 2025-06-02 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態

Country Status (15)

Country Link
US (4) US10669236B2 (enExample)
EP (1) EP3679016B1 (enExample)
JP (3) JP2020533412A (enExample)
KR (2) KR102691700B1 (enExample)
CN (2) CN111278808B (enExample)
AU (2) AU2018330163B2 (enExample)
BR (1) BR112020004419A2 (enExample)
CA (1) CA3074831A1 (enExample)
DK (1) DK3679016T3 (enExample)
FI (1) FI3679016T3 (enExample)
IL (1) IL272992A (enExample)
MX (2) MX2020002622A (enExample)
SG (1) SG11202001868RA (enExample)
TW (1) TWI815820B (enExample)
WO (1) WO2019051147A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
HUP0400446A2 (hu) * 2001-05-22 2004-09-28 Pfizer Products Inc. Azitromicin kristályformái
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JP2008522983A (ja) * 2005-09-13 2008-07-03 シコール インコーポレイティド ロクロニウムブロミドの合成方法
DK2041071T3 (da) * 2006-06-29 2014-09-01 Kinex Pharmaceuticals Llc Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
BRPI0717554A2 (pt) * 2006-09-28 2013-10-29 Merck & Co Inc Composição farmacêutica, método para tratar câncer e aliviar os efeitos colaterais do inibidor da hdac, e, método de se obter um complexo de quelato inibidor da hdac de metal
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
CN101778855A (zh) * 2007-05-22 2010-07-14 阿尔迪默菲克斯技术有限责任公司 替诺福韦酯半富马酸共晶体
WO2015069217A1 (en) 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
BR112019018687A2 (pt) 2017-03-10 2020-04-07 Athenex, Inc. métodos de tratamento e/ou prevenção da ceratose actínica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005248347 *

Also Published As

Publication number Publication date
KR20240119192A (ko) 2024-08-06
US20190071402A1 (en) 2019-03-07
AU2018330163A1 (en) 2020-03-26
KR20200081359A (ko) 2020-07-07
US12215083B2 (en) 2025-02-04
SG11202001868RA (en) 2020-03-30
KR102691700B1 (ko) 2024-08-02
JP2025131661A (ja) 2025-09-09
MX2023001805A (es) 2023-03-13
JP2023157909A (ja) 2023-10-26
AU2023201010B2 (en) 2024-10-03
US20250115555A1 (en) 2025-04-10
EP3679016B1 (en) 2025-11-05
US20200255380A1 (en) 2020-08-13
CN111278808B (zh) 2024-04-26
TWI815820B (zh) 2023-09-21
WO2019051147A1 (en) 2019-03-14
CA3074831A1 (en) 2019-03-14
RU2020112539A3 (enExample) 2022-04-19
FI3679016T3 (fi) 2025-12-12
CN118439992A (zh) 2024-08-06
US10669236B2 (en) 2020-06-02
CN111278808A (zh) 2020-06-12
MX2020002622A (es) 2020-10-01
US20220098152A1 (en) 2022-03-31
US11230527B2 (en) 2022-01-25
DK3679016T3 (da) 2025-12-15
IL272992A (en) 2020-04-30
AU2023201010A1 (en) 2023-03-23
TW201920160A (zh) 2019-06-01
BR112020004419A2 (pt) 2020-09-08
RU2020112539A (ru) 2021-10-08
EP3679016A1 (en) 2020-07-15
EP3679016A4 (en) 2021-09-29
AU2018330163B2 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
CN102510855B (zh) N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形
JP2023157909A (ja) ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
EP3394070B1 (en) Crystalline forms of quinolone analogs and their salts
US20170166590A1 (en) Crystalline forms of quinolone analogs and their salts
WO2022240886A1 (en) Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
JP7784424B2 (ja) テガビビントの結晶形態、調製方法、及びその使用
JP2022179783A (ja) キノロン類似体及びその塩の結晶形
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
CN102666528A (zh) 晶体cdc7 抑制剂盐
TWI765848B (zh) 喹諾酮類似物及其鹽的結晶形式
HK40098923A (en) Crystalline forms of quinolone analogs and their salts
TW202328073A (zh) Ｅｐ４拮抗劑化合物及其鹽、多晶型及其製備方法和用途
WO2024217521A1 (zh) 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物枸橼酸盐的晶型、制备方法及其应用
JP2018525436A (ja) オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法
HK1262794B (en) Crystalline forms of quinolone analogs and their salts
HK1262794A1 (en) Crystalline forms of quinolone analogs and their salts

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210820

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230301

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231120

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240202

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240822

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022